Search research articles
Contact Us
Filters
Showing results (471-480 of 493) with videos related to
Page
of 50
Sort By:
Lancet (London, England)
|
May 14, 2019
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial
Brian I Rini, Thomas Powles, Michael B Atkins, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 18, 2026
Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti-PD-1 Therapy in Clear Cell Renal Cell Carcinoma: analyses of the HCRN GU16-260 trial
Nourhan El Ahmar, Morgan A Paul, Berkay Simsek, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 15, 2018
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
Julie R Brahmer, Christina Lacchetti, Bryan J Schneider, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 1, 2021
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update
Bryan J Schneider, Jarushka Naidoo, Bianca D Santomasso, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 27, 2014
The high-dose aldesleukin "select" trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma
David F McDermott, Su-Chun Cheng, Sabina Signoretti, et al.
Journal for Immunotherapy of Cancer
|
June 1, 2018
An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0
Ryan J Sullivan, Michael B Atkins, John M Kirkwood, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 1, 2021
Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline
Bianca D Santomasso, Loretta J Nastoupil, Sherry Adkins, et al.
Nature Medicine
|
October 7, 2018
Publisher Correction: Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
David F McDermott, Mahrukh A Huseni, Michael B Atkins, et al.
The New England Journal of Medicine
|
June 5, 2012
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer
Suzanne L Topalian, F Stephen Hodi, Julie R Brahmer, et al.
Nature Medicine
|
June 6, 2018
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
David F McDermott, Mahrukh A Huseni, Michael B Atkins, et al.
Page
of 50
Search research articles
Search
Showing results (471-480 of 493) with videos related to
Sort By:
Page
of 50
Lancet (London, England)
|
May 14, 2019
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial
Brian I Rini, Thomas Powles, Michael B Atkins, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 18, 2026
Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti-PD-1 Therapy in Clear Cell Renal Cell Carcinoma: analyses of the HCRN GU16-260 trial
Nourhan El Ahmar, Morgan A Paul, Berkay Simsek, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 15, 2018
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
Julie R Brahmer, Christina Lacchetti, Bryan J Schneider, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 1, 2021
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update
Bryan J Schneider, Jarushka Naidoo, Bianca D Santomasso, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 27, 2014
The high-dose aldesleukin "select" trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma
David F McDermott, Su-Chun Cheng, Sabina Signoretti, et al.
Journal for Immunotherapy of Cancer
|
June 1, 2018
An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0
Ryan J Sullivan, Michael B Atkins, John M Kirkwood, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 1, 2021
Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline
Bianca D Santomasso, Loretta J Nastoupil, Sherry Adkins, et al.
Nature Medicine
|
October 7, 2018
Publisher Correction: Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
David F McDermott, Mahrukh A Huseni, Michael B Atkins, et al.
The New England Journal of Medicine
|
June 5, 2012
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer
Suzanne L Topalian, F Stephen Hodi, Julie R Brahmer, et al.
Nature Medicine
|
June 6, 2018
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
David F McDermott, Mahrukh A Huseni, Michael B Atkins, et al.
Page
of 50